New treatment strategy tested for older myeloma patients
NCT ID NCT04656951
Summary
This study is testing a treatment plan for older adults with multiple myeloma who are not eligible for a stem cell transplant. It adds a drug called daratumumab to a standard three-drug combination for initial treatment, followed by long-term maintenance therapy. The goal is to see if this approach is safe, effective at controlling the cancer, and still works if the disease returns and needs to be treated again.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Cologne
Cologne, 50937, Germany
Conditions
Explore the condition pages connected to this study.